TNFSF10 and cancer: The major limitations of using the TRAIL in cancer treatment are its relatively short half-life and rapid clearance from the blood circulation, limiting its effectiveness in reaching tumors at therapeutic levels.3–5 This short half-life requires repeated and prolonged administration of the TRAIL, which can be challenging in terms of patient compliance and potential toxicity.3 Overcoming these challenges requires ongoing research to develop strategies that enhance the therapeutic potential of the TRAIL.